In December 2025, a federal panel combined 21 Ozempic and related GLP-1 vision loss lawsuits into a multidistrict litigation (MDL) in the Eastern District of Pennsylvania
for example, coronary heart disease, or in those that have a BMI lower than 35kg/m 2 and for whom insulin therapy would have significant occupational implications[15]
The new dose gives healthcare professionals even more flexibility to tailor treatment and help people with obesity achieve their weight loss and health goals. Sources Novo Nordisk announces significant reduction in US list price for Wegovy, Ozempic, and Rybelsus (semaglutide medicines), building on continued efforts to expand access
Concurrent medications must be considered, particularly for oral semaglutide, which requires a 30-minute separation from other medications and food
The injection is absorbed more predictably since its injected under the skin